| 영문 | apoptosis | 한글 | 세포자멸사, 아포프토시스 |
|---|---|---|---|
| 설명 | 합목적적으로 발현되는 프로그램된 세포사를 말한다. 종래에는 세포사란 괴사 즉 화상 등으로 인하여 한무리의 세포가 죽는 것이라 이해되었으나 1972년 Kerr, Wylliie, Currie의 세 병리학자가 형태적으로 명백하게 다른 또 하나의 세포사를 발견하고 이를 아포푸토시스라고 정의했다. 그 뒤의 연구를 통해 발생단계에서 어느 특정세포가 일정시기, 장소, 순서에 의해죽어감으로써 정상적인 발생이 완료하는 것으로 알려졌으며 특별히 프로그램 세포라 부르는 때도 있다. 또한 가슴샘을 중심으로 하는 면역계의 발달과정에서도 이 세포사는 매우 중요한 역할을 한다는 점, 여러 가지 병과의 관련에 있어서 유전자 수준의 해석을 통한 암관련 유전자, 증식유전자 등과의 복잡한 관련도 알려져 있다. 형태적으로 괴사는 세포전체나 사립체가 서서히 팽창되고 세포질의 변화가 선행되며 최종적으로 세포막의 파괴가 일어나는데 비해, 세포자멸사에서는 DNA의 단편화가 선행되고 그 결과 염색질이 핵막주변에 응집하여 핵농축, 핵용해가 일어나며 거의 동시에 세포의 축소라든가 융모 등의 소실되고 결국 세포 전체가 막에 쌓인 크고 작은 세포자멸사 소체로 단편화되고 최종적으로 비염증적으로 큰포식세포에 탐식된다. 세포자멸사는 괴사와 대립적으로 이해되어 왔지만 최근 들어 이들 두가지 세포죽음의 형태의 공통점도 많이 부각되고 있다. |
||
| 영문 | serum proteins | 한글 | 혈청단백 |
|---|---|---|---|
| 설명 | 혈청에 있는 단백질들을 총칭하는 말로, 면역글로불린(면역현상에 관여하는 항체를 형성함), 알부민, 보체 및 응고인자와 여러 효소들이 이에 속한다. |
||
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
|---|---|
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| PBPs | Penicillin-Binding Proteins |
| PVM | pneumonia virus of mice; proteins, vitamins, and minerals |
| RPSP | reference preparation for serum proteins |
| IAP | Inhibitor of Apoptosis |
|---|---|
| IAP | Inhibitor of apoptosis protein |
| NAIP | Neuronal Apoptosis Inhibitor Protein |
| X-IAP | X-linked inhibitor of apoptosis protein |
| G proteins | GIP-binding proteins |
| apoptosis | <cell biology> Programmed cell death as signalled by the nuclei in normally functioning human and animal cells when age or state of cell health and condition dictates. An active process requiring metabolic activity by the dying cell, often characterised by cleavage of the DNA into fragments that give a so called laddering pattern on gels. Cells that die by apoptosis do not usually elicit the inflammatory responses that are associated with necrosis, though the reasons are not clear. Cancerous cells, however, are unable to experience the normal cell transduction or apoptosis-driven natural cell death process. See: ced mutant, bcl. (18 Nov 1997) |
|---|---|
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
| carbonic acid inhibitor | <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma. (27 Sep 1997) |
| carbonic anhydrase inhibitor | <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma. Examples include acetazolamide, dichlorphenamide and methazolamide. (27 Sep 1997) |
| mammary derived growth inhibitor | Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells. (18 Nov 1997) |
| mechanism-based inhibitor | A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme. Synonym: mechanism-based inhibitor. (05 Mar 2000) |
| glucosidase inhibitor | Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence. (05 Mar 2000) |
Synonyms : Baculoviral Inhibitor Of Apoptosis Repeat Proteins, IAP Protein (Apoptosis), IAP1 Protein, IAP2 Protein, Inhibitor of Apoptosis 1 Protein, Inhibitor of Apoptosis 2 Protein, Inhibitor-Of-Apoptosis Protein, c-IAP1 Protein, c-IAP2 Protein, cIAP1 Protein
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|